3.70
0.00 (0.00%)
| Previous Close | 3.70 |
| Open | 3.73 |
| Volume | 13,795 |
| Avg. Volume (3M) | 66,369 |
| Market Cap | 31,294,478 |
| Price / Book | 2.58 |
| 52 Weeks Range | |
| Earnings Date | 12 Feb 2026 |
| Diluted EPS (TTM) | -12.30 |
| Total Debt/Equity (MRQ) | 131.68% |
| Current Ratio (MRQ) | 0.550 |
| Operating Cash Flow (TTM) | -17.91 M |
| Levered Free Cash Flow (TTM) | -6.55 M |
| Return on Assets (TTM) | -62.86% |
| Return on Equity (TTM) | -244.55% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Cel-Sci Corporation | - | - |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -2.5 |
| Average | 0.63 |
|
CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research, development, and manufacturing of immune systems for the treatment of cancer and other diseases. The company's lead investigational immunotherapy is Multikine, a Leukocyte Interleukin injection, which has completed a pivotal Phase 3 clinical trial for patients, who are diagnosed with locally advanced primary squamous cell carcinoma of the head and neck. It is also developing Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer. In addition, the company is developing CEL-2000 and CEL-4000 which are LEAPS based product candidates for the treatment of rheumatoid arthritis disease. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 0.98% |
| % Held by Institutions | 3.80% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Mai Capital Management | 31 Dec 2025 | 89,723 |
| Us Bancorp \De\ | 31 Dec 2025 | 18,413 |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 29 Dec 2025 | Announcement | CEL-SCI Reports Fiscal 2025 Results |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |